<DOC>
	<DOCNO>NCT00659685</DOCNO>
	<brief_summary>Single-dose cross comparative bioavailability Ondansetron 16 mg ODT Zofran 16 mg ODT</brief_summary>
	<brief_title>Bioavailability Study Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions</brief_title>
	<detailed_description>To Compare single-dose bioavailability Kali 's Ondansetron 16 mg ODT GlaxoSmithKine 's Zofran 16 mg ODT fasting condition</detailed_description>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Availability subject entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly sign volunteer Males females age 18 55 year body mass index ( BMI ) great equal 19 30 kg/ m2 Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance ( laboratory test present section 6.1.1.3 ) Healthy accord laboratory result physical examination . Non ex smoker Significant history hypersensitivity ondansetron related product well severe hypersensitivity reaction ( like angioedema ) drug . Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease . Females pregnant , lactate likely become pregnant study phase . Females childbearing potential refuse use acceptable contraceptive regimen throughout body . Positive serum pregnancy test study . Maintenance therapy drug , significant history drug dependancy , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) . Any clinically significant illness previous 28 day day 1 study . Use enzymemodifying drug previous 28 day 1 day study ( barbiturate , corticosteroid , phenylhydantoins , etc. ) . Participation another clinical trial previous 28 day day 1 study . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . Positive urine screening drug abuse ( drug names present section 6.1.1.4 ) . Positive result HIV , HBsAg antiHCV test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Ondansetron ODT</keyword>
	<keyword>Fasting</keyword>
	<keyword>To Determine Bioequivalence Under Fasting condition</keyword>
</DOC>